Male patients exhibited shorter OS compared to female patients, particularly when receiving EGFR-TKI treatment or during specific clinical stages (e.g., early lymph node metastasis, no distant metastasis, no brain metastasis, or undergoing surgical treatment), where the prognosis for males was markedly worse. The gene discussed is EGFR; the disease is metastatic malignant neoplasm in the lymph nodes.